Secondary metabolites of oil palm isolates of Ganoderma zonatum murill. from cameroon and their cytotoxicity against five human tumour cell lines

African Journal of Biotechnology

Volumn 10, Issue 42, 2011, Pages 8440-8447

  Kinge, Tonjock R ^a   Mih, Afui M ^a  

^a UNIVERSITY OF BUEA   (Cameroon)

Author keywords

Chemotaxonomic character; Cytotoxicity; Ganoderma zonatum; Secondary metabolites

Indexed keywords

15,26 DIHYDROXYLANOSTA 7,9(11),24 TRIEN 3 ONE; 22,24 ERGOSTA 7,22 DIEN 3BETA,5ALPHA,6BETA TRIOL; 3 HYDROXYLANOSTA 7,9(11),24 TRIEN 26 OIC; 5,6 DIHYDROERGOSTEROL; 5ALPHA,8ALPHA EPIDIORY 22,24 ERGOSTA 6,22 DIEN 3BETA OL; ANTINEOPLASTIC AGENT; CISPLATIN; ERGOSTEROL; FUNGAL EXTRACT; GANODERIC ACID Y; GANODERMA ZONATUM EXTRACT; PACLITAXEL; PHTHALIC ACID DIMETHYL ESTER; STEROID; TRITERPENOID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CAMEROON; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; GANODERMA; GANODERMA ZONATUM; HUMAN; HUMAN CELL; IC 50; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY; TUMOR CELL LINE;

ELAEIS; GANODERMA; GANODERMA ZONATUM;

EID: 80051778764     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: 10.5897/ajb10.2144     Document Type: Article

References (35)

1. Alexopoulos CJ, Mims CW, Blackwell M (1996). Introductory Mycology (4th edition). New York John Wiley. p. 869
2. Arisawa M, Fujita M, Fukumura S, Hayashi T, Morita N (1986). Three new Lanostanoids from Ganoderma lucidium. J. Natural Products (Lloydia). 49: 621-625.
3. Berger A, Rein D, Kratky E, Monnard I, Hajjaj H, Meirim I, Piguet-Welsch C, Hauser J, Mace K, Niederberger P (2004). Cholesterollowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids Health Dis. pp. 1-12.
4. Chang R (1996). Functional Properties of Edible Mushrooms. Nutr. Rev. 54: 91-93.
5. Chang ST, Buswell JA (1996). Mushroom nutriceutical. World J. Microbiol. Biotechnol.12(5): 473-476.
6. Chang ST, Mshigeni KE (2001). Mushroom and Human Health: their growth significance as petentdietary supplement, University of Namibia, Windhoek, p. 79.
7. Chen HS, Tsai YF, Lin S, Lin CC, Khoo KH, Lin CH, Wong CH (2004). Studies on the immune-modulating and anti-tumor activities of Ganoderma lucidum(Reishi) polysaccharides. Bioorganic Med. Chem., 12: 5595-5601.
8. Chiu SW, Wang ZM, Leung TM, Moore D (2000). Nutritional value of Ganoderma extract and Assesment of its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chem. Toxicol., 38: 173-178.
9. Gao B, Yang G (1991). Effect of Ganoderma applanatum polysaccharides on cellularand humoral immunity in normal and sarcoma 180 transplanted mice. Phytopathol. Res., 5: 134-138.
10. Hajjaj H, Mace C, Roberts M, Niederberger P, Fay LB (2005). Effect of 26-oxygenosterols from Ganoderma lucidium and their activity as cholesterol synthesis inhibitors. Applied and Environ. Microbiol., 71(7): 3653-3658.
11. Huie CW, Di X (2004).Chromatographic and electrophoretic methods for Lingzhi pharmacologically active components. J. chromatogr., 812: 241-257.
12. Jong SC, Birmingham JM (1991). Medicinal benefit of the mushroom Ganoderma. Adv. Appl. Microbiol., 37: 104-132.
13. Jong SC, Birmingham JM (1992). Medicinal benefits of the mushroom Ganoderma. Adv. Appl. Microbiol., 34: 183-262.
14. Kim HW, Kim BK (2002).Recent advances on biologically active triterpenoids of Ganoderma lucidum In: Ganoderma Lin ZB (Ed), Beijing Medical university press, Beijing, Genet. Chem. Pharmacol. Ther. pp. 10-19.
15. Komoda Y, Shimizu M, Sonoda Y, Sato Y (1989). Ganoderic acid and derivatives as cholesterol synthesis inhibitors. Chem. Pharm. Bull., 37: 531-533.
16. Lin JY, Chou TB (1984). Isolation and characterization of lecitin from edible mushroom,Volvariella volvacea. J. Biol. Chem., 96: 135-140.
17. Lindequist U, Niedermeyer T, Jülich W (2005). The pharmacological potential of mushrooms. E-CAM, 2(3): 285-299.
18. Liu J (2004). N-containing Compounds of Macromycetes. Chem. Rev., 105(7): 2723-2744.
19. Lorenzen K, Anke Y (1998). Basidiomycetes as a source for new bioactive natural Ganoderma lucidum extract alone and in combination with some antibiotics. Arch. Pharm. Res., 17: 438-442.
20. Lull C, Wichers H, Savelkoul H (2005). Antiinflamatory and Immunomodulating Properties of Fungal Metabolites. Mediators of Inflammation. pp. 63-80.
21. Mizuno T (1999). The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan (Review). Int. J. Med. Mushrooms, 1: 9-30.
22. Paterson RRM (2006). Ganoderma-A therapeutic fungal biofactory. Phytochemistry, 67: 1985-2001.
23. Roja G, Rao PS (1998). Biotechnology investigation in medicinal plants for the product ion of secondary metabolites In: Role of Biotechnology in medicinal and Aromatic plants (Irfan AA and Atiya K. editors) Hong Kong, 1: p. 201.
24. Shim SH, Ryu J, Kim JS, Kang SS, Xu Y, Jung SH, Lee YS, Lee S, Shin KH (2004). New lanostane- type triterpenoids from Garnoderma applanatum. J. Nat. Prod. 67: 1110-1113.
25. Silva D, Labarrere C, Slivova V, Sedlak M, Lloyad Jr. FP, HO WWY (2002). Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem. Biophys. Res. Commun. 298: 603-612.
26. Stamets P (2000). Mushrooms, civilization and history. In Growing Gourmet and Medicinal Mushrooms. Ten Speed Press. USA, pp. 1-4.
27. Toth JO, Luu B, Ourisson G (1983). Ganoderic acid T and Z: Cytotoxic triterpenes from Ganoderma lucidum (Polyporaceae). Tetrahedron Lett., 24: 1081-1084.
28. Turner PD (1981). Oil Palm Diseases and Disorders. Kuala Lumpur: Oxford University Press, p. 281.
29. Turner WB (1971). Fungi, their cultivation and their secondary metabolism. In Fungal Metabolites. Academic Press England, pp. 11-23.
30. Utomo C, Werner S, Niepold F, Deising HB (2005). Identification of Ganoderma, the causal agent of basal stem rot disease in oil palm, using a molecular method. Mycopathologia, 159: 159-170
31. Wasser SP, Weis AL (1999b). Medicinal properties of substances occurring in higher basidiomycetes mushrooms: current perspectives (Review). Int. J. Med. Mushroom, 1: 31-62.
32. Wasser SP, Weis AL(1999a). General description of the most important medicinal higher basidiomycetes mushrooms. Int. J. Med. Mushroom, 1: 351-370.
33. Wasser SP, Weis AL (1999). Therapeutic Effects of substances occurring in Higher Basidiomycetes Mushrooms: a Modern Perspective. Crit. Rev. Immunol., 19: 65-96.
34. Yongabi K, Agho M, Carrera MD (2004). Ethnomycological studies of wild mushrooms in Cameroon, Central Africa. Mycologia Applicada Int., pp. 34-36.
35. Yoon SY, EO SK, Kim YS, Lee CK, Han SS (1994). Antimicrobial activity of Ganoderma extract alone and in combination with some antibiotics. Arch. Pharmacol. Res., 17(6): 438-442.